Idealp Pharma Lead-To-Candidate

About Idealp-Pharma	Company Profile \| People \| Contact \|
Integrated Drug Discovery	Hit Discovery and Validation \| Hit-To-Lead \| Lead-To-Candidate \|
Stand Alone Services	Chemistry \| Cheminformatics \|
Emerging projects
Work Practices

Lead-To-Candidate

Delivering INDs candidates

Medicinal Chemistry
Our scientists refine SARs against previouly generated data and following discussion with chemists, biologists and computational chemists. The aim is to pick up and optimise leads with the best chances of being active in vivo. We also synthesise metabolites in order to monitor their biological activity.

Cheminformatics
Drug selectivity and secondary target identification can be checked by inverse virtual screening. We can identify secondary targets for a known hit/lead via proprietary in silico strategies. In silico ligand profiling helps address potency and selectivity issues and thus anticipates pharmacological side effects for your ligand.

Exploratory in vivo ADMET
We have partnerships with acknowledged specialists in early in vivo bioavailability and toxicity studies for the most promising lead compounds upstream in drug discovery process in order to confirm previous in vitro ADMET results.

Non-clinical development
Idealp-Pharma can manage its customers' preclinical development of its clients because drug discovery, optimisation and development are all interlinked. We help our customers to complete their requirements for INDs and IMPDs : preliminary formulation, scale-up, toxicology studies, CMC, safety pharmacology, and genotoxicity .

These services are aimed at giving to the test compound the best possible chances of being active in animal models.